【摘要】 目的:探究帕罗西汀和奥氮平分别联合氟哌噻吨美利曲辛治疗脑卒中后抑郁患者的生活质量影响。方法:选取2017年2月至2019年4月我院脑卒中抑郁患者126例,以随机数字表法简单随机分组为3组,帕罗西汀联合组、奥氮平联合组和对照组各42例。帕罗西汀联合组行帕罗西汀联合氟哌噻吨美利曲辛治疗,奥氮平联合组行奥氮平联合氟哌噻吨美利曲辛治疗,对照组单独行氟哌噻吨美利曲辛治疗,疗程均为8周。对比三组的治疗疗效、NIHSS、HAMD、BI评分、不良反应发生情况。结果:帕罗西汀联合组与奥氮平联合组的治疗疗效优于对照组(Z=3.063、2.301,P均<0.05);帕罗西汀联合组与奥氮平联合组的总有效率分别为95.24%、90.48%,明显高于对照组的73.81%(P <0.0167)。治疗后三组NIHSS、HAMD评分明显降低(P<0.05),BI评分明显升高(P<0.05);治疗后帕罗西汀联合组与奥氮平联合组的NIHSS、HAMD明显低于对照组(P<0.05),BI评分明显高于对照组(P<0.05)。帕罗西汀联合组、奥氮平联合组、对照组患者治疗后总不良反应发生率分别为66.67%、80.95%、78.57%,三组总不良反应发生率比较,差异无统计学意义(P>0.05)。结论:相对于单独使用氟哌噻吨美利曲辛,帕罗西汀联合氟哌噻吨美利曲辛和奥氮平联合氟哌噻吨美利曲辛应用于脑卒中抑郁患者,治疗疗效显著,可有效降低神经功能缺损和抑郁程度,提高生活能力,不会增加不良反应。更多还原

【Abstract】 Objective: To investigate the effect of paroxetine and olanzapine respectively combined with flupentixol-melitracen on the quality of life of post-stroke depression patients. Methods: From February 2017 to April 2019,126 patients with stroke depression in our hospital were randomly divided into 3 groups by random number table method,42 cases each in paroxetine combination group,olanzapine combination group and control group. Paroxetine combination group received paroxetine combined with flupentixol-melitracen,olanzapine combination group received olanzapine combined with flupentixol-melitracen,and the control group received flupentixol-melitracen alone treatment. The course of treatment is 8 weeks. The treatment efficacy,NIHSS,HAMD,BI score,and adverse reactions of the three groups were compared. Results: The therapeutic effect of the paroxetine combination group and olanzapine combination group was better than that of the control group( Z = 3.063,2.301,P <0.05); The total effective rates of the paroxetine combination group and olanzapine combination group were 95.24% and 90.48%,significantly higher than 73.81% of the control group( P <0.0167). After treatment,the NIHSS and HAMD scores of the three groups were significantly decreased( P <0.05),and the BI score was significantly increased( P <0.05); NIHSS and HAMD of the paroxetine combineation group and olanzapine combination group were significantly lower than that of the control group( P <0.05),the BI score was significantly higher than the control group( P <0.05). The incidences of total adverse reactions in the paroxetine combination group,olanzapine combination group and control group after treatment were66.67%,80.95% and 78.57% respectively. There was no statistically significant difference in the incidence of total adverse reactions among the three groups( P >0.05). Conclusion: Paroxetine combined with flupentixol-melitracen and olanzapine combined with flupentixol-melitracen in stroke patients with depression has a significant therapeutic effect compared with the use of flupentixol-melitracen alone. It can effectively reduce the degree of neurological deficit and depression,improve the ability of life,and will not increase adverse reactions.更多还原